Update
$Pluri Inc(PLUR.US$ Pluri Says US NIAID Will Provide Company With $1.4M From July 1, 2024 To June 30, 2025; NIAID Exercised Its Option For Year Two Of The Three-year $4.2M Contract It Entered Into With Pluri In July 2023
Benzinga· just
The company will manufacture the PLX-R18 cell therapy and to conduct both in vitro and in vivo studies to develop PLX-R18 as a potential novel treatment for hematopoietic complications of the acute radiation syndrome (H-ARS).
Benzinga· just
The company will manufacture the PLX-R18 cell therapy and to conduct both in vitro and in vivo studies to develop PLX-R18 as a potential novel treatment for hematopoietic complications of the acute radiation syndrome (H-ARS).
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
